Phase 1 Immunodeficiency Clinical Trials
13 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–13 of 13 trials
Recruiting
Phase 1Phase 2
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
X-linked Severe Combined Immunodeficiency (XSCID)
National Institute of Allergy and Infectious Diseases (NIAID)40 enrolled1 locationNCT01306019
Recruiting
Phase 1
Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy
Human Immunodeficiency Virus
National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT06819176
Recruiting
Phase 1Phase 2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 1
HIV Therapeutic DNA Vaccine (ICVAX) Phase I Clinical Trial in Hong Kong
Human Immunodeficiency VirusHuman Immunodeficiency Virus I Infection
Immuno Cure Holding (HK) Limited22 enrolled1 locationNCT07530198
Recruiting
Phase 1Phase 2
Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)
Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency
Assistance Publique - Hôpitaux de Paris7 enrolled1 locationNCT05071222
Recruiting
Phase 1Phase 2
Autologous Gene Therapy for Artemis-Deficient SCID
Severe Combined Immunodeficiency
University of California, San Francisco24 enrolled1 locationNCT03538899
Recruiting
Phase 1
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
Viral InfectionHematopoietic Stem Cell Transplantation (HSCT)Primary Immunodeficiency Disorders (PID)
Children's National Research Institute48 enrolled3 locationsNCT04691622
Recruiting
Phase 1
The DART DELIVER-02 Study
HIV (Human Immunodeficiency Virus)
University of North Carolina, Chapel Hill24 enrolled3 locationsNCT07217379
Recruiting
Phase 1Phase 2
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Gene TherapySevere Combined Immunodeficiency, X-Linked
David Williams12 enrolled4 locationsNCT03311503
Recruiting
Phase 1
Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults
Human Immunodeficiency Virus
U.S. Army Medical Research and Development Command78 enrolled1 locationNCT06205056
Recruiting
Phase 1Phase 2
Phase Ib/IIa Clinical Study of ACC017 Tablets
Infection, Human Immunodeficiency Virus
Jiangsu Aidea Pharmaceutical Group Co., Ltd.36 enrolled1 locationNCT06719310
Recruiting
Phase 1
Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency
Severe Combined Immunodeficiency, X-Linked
Great Ormond Street Hospital for Children NHS Foundation Trust5 enrolled1 locationNCT03601286
Completed
Phase 1
A trial of BIT225 in patients with HIV-1 infection, to study the safety, concentration and distribution in the body, and anti-viral activity of the drug.
Human Immunodeficiency Virus-1 infection
Biotron Limited24 enrolled1 locationACTRN12612000696897